Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour

État Nombre total Résumé
En négociation 38 Non liées à l’oncologie : 21
Liées à l’oncologie : 17
Négociations envisagées 20 Non liées à l’oncologie : 11
Liées à l’oncologie : 9
Négociations terminées 898 Avec lettre d’intention : 776
Sans entente : 122
Négociations qui n’ont pas eu lieu 113

Activités de l’APP dans les quatre dernières semaines

Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.

Lettres d’engagement transmises au cours des quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Sarclisa Sanofi Genzyme Canada In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).
Epuris Cipher Acne Vulgaris
Rebyota Ferring Canada Inc. Clostridioides difficile infection, prevention
Lyvdelzi Gilead Sciences Canada Inc. For the treatment of primary biliary cholangitis (PBC), in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in adults unable to tolerate UDCA.
Quviviq Idorsia Pharmaceuticals Canada Ltd. Insomnia
Alyftrek Vertex Pharmaceuticals (Canada) Incorporated Cystic fibrosis, F508del or responsive CFTR mutation, 6 years and older
Perjeta Hoffmann-La Roche Ltd. In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with early-stage HER2-positive breast cancer
Ranvu Apotex Inc. Multiple Indications
Carvykti Janssen Inc. (du) Multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment
Carvykti Janssen Inc. For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
Calquence AstraZeneca Canada Inc. Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL.
Venclexta AbbVie Corporation Calquence, in combination with venetoclex, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)
Verzenio Eli Lilly Canada Inc. For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy.
Verzenio Eli Lilly Canada Inc. For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: • in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. • in combination with fulvestrant in women with disea

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Voranigo Servier Canada Inc. For the treatment of Grade 2 WHO 2016, 2021 grading system astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation or isocitrate dehydrogenase-2 (IDH2) mutation in adults and pediatric patients aged 12 years and olde
Mavenclad EMD Serono Canada, a division of EMD Inc. Multiple Sclerosis, Relapsing-Remitting
Opdivo-Yervoy Bristol Myers Squibb Canada Inc. For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
Rybrevant Janssen Inc. Non-small cell lung cancer (NSCLC), Locally advanced or metastatic, in adult patients with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations whose disease has progressed on, or after platinum-based chemotherapy
Lazcluze and Rybrevant Janssen Inc. For the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR)
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, who
Darzalex SC Janssen Inc. in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Ofev Boehringer Ingelheim (Canada) Ltd. Idiopathic pulmonary fibrosis and PF-ILD
Spevigo Boehringer Ingelheim (Canada) Ltd. generalized pustular psoriasis (GPP)

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines

Marque Fabricant Indication Aucune date de négociation

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines